| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Unrealized gains (losses) on investments | 0 | 0 | - | 15 |
| Other comprehensive income (loss), foreign currency transaction and translation gain (loss) arising during period, net of tax | -1 | 1 | - | - |
| Cost of goods sold | 10,996 | 11,898 | 8,728 | 13,593 |
| Research and development | 7,483 | 8,055 | 7,753 | 5,888 |
| Selling, general and administrative | 46,459 | 44,393 | 44,018 | 44,969 |
| Amortization of intangible assets | 2,711 | 2,711 | 2,710 | 2,711 |
| Total costs and expenses | 67,649 | 67,057 | 63,209 | 67,161 |
| Product revenue, net | 74,380 | 71,539 | 60,119 | 54,268 |
| Income (loss) from operations | 6,731 | 4,482 | -3,090 | -12,893 |
| Interest and other income | 1,158 | 948 | 1,175 | 1,197 |
| Debt refinancing costs | 0 | 0 | - | - |
| Interest expense | 7,268 | 7,358 | 7,305 | 7,786 |
| Change in fair value of warrants | 0 | 0 | - | - |
| Change in fair value of contingent value rights | 0 | 0 | - | -420 |
| Total other expense | -6,110 | -6,410 | -6,130 | -6,169 |
| Net income (loss) before income taxes | 621 | -1,928 | -9,220 | -19,062 |
| Income tax benefit | 0 | 0 | - | -3,324 |
| Net income (loss) | 621 | -1,928 | -9,220 | -15,738 |
| Comprehensive income (loss) | 620 | -1,927 | -9,220 | -15,723 |
| Net loss per common share - basic (in dollars per share) | 0 | -0.01 | -0.06 | -0.11 |
| Net loss per common share - diluted (in dollars per share) | 0 | -0.01 | -0.06 | -0.11 |
| Weighted average common shares outstanding - basic (in shares) | 163,649,932 | 159,459,413 | 152,445,935 | 148,993,823 |
| Weighted average common shares outstanding - diluted (in shares) | 177,617,307 | 159,459,413 | 152,445,935 | 148,993,823 |
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)